Catheter Precision (NYSEAMERICAN:VTAK) Releases Earnings Results, Beats Expectations By $18.02 EPS

Catheter Precision (NYSEAMERICAN:VTAK) announced its quarterly earnings data on Tuesday. The company reported ($2.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($20.90) by $18.02, FiscalAI reports. Catheter Precision had a negative return on equity of 208.54% and a negative net margin of 2,333.29%.

Catheter Precision Trading Down 3.8%

Shares of VTAK stock traded down $0.04 during trading hours on Tuesday, hitting $1.01. The company’s stock had a trading volume of 112,379 shares, compared to its average volume of 3,183,459. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.20. The business has a fifty day moving average of $1.60 and a 200-day moving average of $2.04. Catheter Precision has a twelve month low of $1.01 and a twelve month high of $15.68.

Institutional Trading of Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC acquired a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision as of its most recent SEC filing. Hedge funds and other institutional investors own 20.34% of the company’s stock.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.